Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

September 22, 2019

Study Completion Date

December 19, 2020

Conditions
SepsisPneumoniaGram-Negative Bacteria InfectionMultiple Organ FailureRespiratory Distress SyndromeMortalityBiomarkers
Interventions
DRUG

Clarithromycin

Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.

DRUG

Water for injection

Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days

Trial Locations (12)

1000

Intensive Care Unit, Saint-Pierre University Hospital, Brussels

1020

Intensive Care Unit, Brugmann University Hospital, Brussels

1070

Intensive Care Unit, Erasme University Hospital, Brussels

11526

Intensive Care Unit, Korgialeneio-Benakeio General Hospital, Athens

11527

Intensive Care Unit, Laikon General Hospital, Athens

12462

2nd Department of Intensive Care Medicine, Attikon University Hospital, Athens

4th Department of Internal Medicine, Attikon University Hospital, Athens

15126

2nd Department of Internal Medicine, Sismanogleio General Hospital, Athens

54 634

Intensive Care Unit, Agios Dimitrios General Hospital, Thessaloniki

546 35

Intensive Care Unit, G. Gennimatas General Hospital, Thessaloniki

546 39

Intensive Care Unit, Theageneio Oncological Hospital, Thessaloniki

546 42

Intensive Care Unit, Ippokrateion General Hospital, Thessaloniki

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Hellenic Institute for the Study of Sepsis

OTHER

NCT03345992 - Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System | Biotech Hunter | Biotech Hunter